Samuel Obeng

Samuel Obeng, Ph.D.

Assistant Scientist

Department: Pharmacodynamics
Business Email: obengs@ufl.edu

About Samuel Obeng

Samuel Obeng, Ph.D., was appointed as an assistant scientist in the College of Pharmacy, Department of Pharmacodynamics in July 2019. Obeng received his Bachelor of Pharmacy and M.Phil. Pharmaceutical Chemistry degrees from Kwame Nkrumah University of Science and Technology, and his Ph.D. in Medicinal Chemistry from Virginia Commonwealth University, Department of Medicinal Chemistry. Upon completion of his doctoral studies, Obeng completed a 1-year postdoctoral fellowship under the supervision of Dr. Yan Zhang and Dr. Dana Selley in the Departments of Medicinal Chemistry and of Pharmacology and Toxicology at Virginia Commonwealth University. Obeng then joined the University of Florida College of Pharmacy in July 2018 as a postdoctoral research associate in the Department of Pharmacodynamics working in both Dr. Lance McMahon and Dr. Christopher McCurdy’s laboratories. Obeng has keen interest in the design, discovery and development of novel opioid ligands for the treatment of pain and opioid use disorder.

Publications

2020
Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for Mu-Opioid Receptor and Opioid-Like Behavioral Effects in Rats.
The Journal of pharmacology and experimental therapeutics. [DOI] 10.1124/jpet.120.000189. [PMID] 33384303.
2020
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
Journal of medicinal chemistry. 63(1):433-439 [DOI] 10.1021/acs.jmedchem.9b01465. [PMID] 31834797.
2019
The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats.
Psychopharmacology. 236(9):2725-2734 [DOI] 10.1007/s00213-019-05247-7. [PMID] 31098655.
2018
Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.
ACS chemical neuroscience. 9(12):3028-3037 [DOI] 10.1021/acschemneuro.8b00234. [PMID] 30001114.
2018
In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.
European journal of pharmacology. 827:32-40 [DOI] 10.1016/j.ejphar.2018.03.013. [PMID] 29530590.
2018
Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.
The Journal of pharmacology and experimental therapeutics. 365(1):37-47 [DOI] 10.1124/jpet.117.246439. [PMID] 29330156.
2016
Antinociceptive Interactions between the Imidazoline I2 Receptor Agonist 2-BFI and Opioids in Rats: Role of Efficacy at the μ-Opioid Receptor.
The Journal of pharmacology and experimental therapeutics. 357(3):509-19 [DOI] 10.1124/jpet.116.232421. [PMID] 27056847.

Teaching Profile

Courses Taught
2020
PHA6935 Selected Topics in Pharmacy

Contact Details

Emails:
Business:
obengs@ufl.edu